Fierce Pharma

NOVEMBER 7, 2023

Vertex and CRISPR Therapeutics are up first with a Dec. | But on Tuesday bluebird said that Vertex’s price tag will not factor into how the Massachusetts company will price its treatment. Two long-awaited treatments for sickle cell disease (SCD) are on the docket for FDA decisions next month.

Gene Therapy 86

Gene Therapy Gene 86

Pharmaceutical Technology

APRIL 13, 2023

Released on April 12, the report focuses on bluebird bio’s lovotibeglogene autotemcel and Vertex Pharmaceuticals and CRISPR Therapeutics’ exagamglogene autotemcel or exa-cel and their potential use in treating sickle cell disease. Bluebird already uses a lentiviral vector in its approved gene therapy for beta-thalassemia called Zynteglo.

Gene Therapy 147

Gene Therapy Gene FDA Approval Licensing 147

XTalks

DECEMBER 13, 2023

The landmark approvals were awarded to bluebird bio’s Lyfgenia (lovo-cel) and Vertex Pharmaceuticals and CRISPR Therapeutics’ jointly developed Casgevy (exa-cel). Analysts at Cantor explained that Vertex only has nine centers for Casgevy, including six that also offer Lyfgenia. Vertex-CRISPR’s Casgevy has a US list price of $2.2

Gene Therapy 98

Gene Therapy FDA Approval Gene In-Vivo 98

STAT News

OCTOBER 6, 2022

… Multimillion-dollar prices for a rival’s treatments with the potential to cure rare diseases are “in the right ballpark,” according to Stuart Arbuckle, chief operating officer at Vertex Pharmaceuticals, which is preparing to market its own treatment for sickle-cell disease , Bloomberg News tells us. Even

Gene Therapy 98

Gene Therapy Gene Insulin Drugs 98

Pharmaceutical Technology

APRIL 5, 2023

But access to these treatments continues to remain limited due to high price tags and variable availability across regions. This includes the first potential approval of a CRISPR-based gene therapy called exa-cel , which is developed by CRISPR Therapeutics and Vertex Pharmaceuticals.

Gene Therapy 147

Gene Therapy Gene Engineer Production 147

XTalks

FEBRUARY 27, 2024

With the approval, Vertex Pharmaceuticals and CRISPR Therapeutics’ jointly developed Casgevy also became the first CRISPR/Cas9-based therapy approved in the US. Casgevy (exa-cel) and Lyfgenia (lovo-cel) were the first gene therapies to be approved by the FDA for the treatment of sickle cell disease (SCD).

Research 59

Research Drugs Gene Therapy Clinical Trials 59